目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key secondary sources
2.1.1.2 Key data from secondary sources
2.1.1.3 Objectives of secondary research
2.1.2 PRIMARY RESEARCH
2.1.2.1 Key primary sources
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Company revenue estimation
2.2.1.2 Customer-based market estimation
2.2.1.3 Primary interviews
2.2.2 TOP-DOWN APPROACH
2.3 GROWTH RATE ASSUMPTIONS
2.4 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 BOTULINUM TOXINS MARKET OVERVIEW
4.2 ASIA PACIFIC: BOTULINUM TOXINS MARKET, BY APPLICATION AND COUNTRY, 2024 (USD MILLION)
4.3 BOTULINUM TOXINS MARKET: EMERGING VS. DEVELOPED MARKETS, 2025 VS. 2030 (USD MILLION)
4.4 BOTULINUM TOXINS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increased adoption in therapeutic indications
5.2.1.2 Reduced out-of-pocket expenditure due to sufficient reimbursement schemes
5.2.1.3 Aesthetic consciousness among adults
5.2.1.4 Greater acceptance and normalization of botulinum toxins among millennials and Gen Z
5.2.2 RESTRAINTS
5.2.2.1 Risk of infection and safety concerns
5.2.2.2 Complex regulatory framework and compliance standards
5.2.3 OPPORTUNITIES
5.2.3.1 High growth opportunities in emerging economies
5.2.3.2 Formulation advancements and innovations for improved safety
5.2.4 CHALLENGES
5.2.4.1 High treatment costs
5.2.4.2 Social and cultural barriers
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF BOTULINUM TOXINS, BY KEY PLAYER, 2022-2024
5.4.2 AVERAGE SELLING PRICE TREND OF BOTULINUM TOXINS, BY REGION, 2022-2024
5.5 VALUE CHAIN ANALYSIS
5.5.1 RESEARCH & DEVELOPMENT
5.5.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING
5.5.3 DISTRIBUTION AND MARKETING & SALES
5.5.4 AFTER-SALES SERVICES
5.6 SUPPLY CHAIN ANALYSIS
5.6.1 PROMINENT COMPANIES
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
5.6.3 END USERS
5.7 ECOSYSTEM ANALYSIS
5.7.1 ROLE IN ECOSYSTEM
5.8 INVESTMENT & FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Jet-based delivery systems
5.9.1.2 Facial imaging and mapping systems
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Laser, RF, & ultrasound-based devices
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 3D imaging and AI-based facial mapping
5.10 PATENT ANALYSIS
5.10.1 INNOVATIONS AND PATENT REGISTRATIONS
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA FOR HS CODE 300290, 2020-2024
5.11.2 EXPORT DATA FOR HS CODE 300290, 2020-2024
5.12 KEY CONFERENCES & EVENTS, 2025-2026
5.13 CASE STUDY ANALYSIS
5.13.1 COMMERCIAL PARTNERSHIPS BY ANIKA THERAPEUTICS TO INCREASE MEDICAL AESTHETIC PRODUCT SALES
5.13.2 DIVISION OF BUSINESS BY MERZ BIOPHARMA TO HELP EFFECIENTLY MEET CUSTOMER DEMANDS
5.13.3 COLLABORATIONS BETWEEN CANDELA CORPORATION AND SMES TO STREAMLINE LASER-BASED DEVICES
5.14 REGULATORY ANANLYSIS
5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14.2 KEY REGULATORY GUIDELINES
5.14.2.1 North America
5.14.2.1.1 US
5.14.2.1.2 Canada
5.14.2.2 Europe
5.14.2.2.1 UK
5.14.2.2.2 France
5.14.2.2.3 Germany
5.14.2.3 Asia Pacific
5.14.2.3.1 China
5.14.2.3.2 Japan
5.14.2.3.3 India
5.14.2.4 Latin America
5.14.2.4.1 Brazil
5.14.2.5 Middle East & Africa
5.14.2.5.1 UAE
5.14.3 REGULATORY STANDARDS/APPROVALS
5.15 REIMBURSEMENT SCENARIO ANALYSIS
5.15.1 NORTH AMERICA
5.15.1.1 US
5.15.1.2 Canada
5.15.2 EUROPE
5.15.2.1 UK
5.15.2.2 Germany
5.15.2.3 France
5.15.2.4 Italy
5.15.2.5 Spain
5.15.3 ASIA PACIFIC
5.15.3.1 China
5.15.3.2 Japan
5.15.3.3 India
5.15.3.4 Australia
5.15.4 LATIN AMERICA
5.15.4.1 Brazil
5.15.4.2 Mexico
5.15.5 MIDDLE EAST & AFRICA
5.15.5.1 GCC Countries
5.15.5.2 Africa (Major Economies)
5.16 PORTER'S FIVE FORCE ANALYSIS
5.16.1 THREAT OF NEW ENTRANTS
5.16.2 THREAT OF SUBSTITUTES
5.16.3 BARGAINING POWER OF SUPPLIERS
5.16.4 BARGAINING POWER OF BUYERS
5.16.5 INTENSITY OF COMPETITIVE RIVALRY
5.17 KEY STAKEHOLDERS & BUYING CRITERIA
5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.17.2 BUYING CRITERIA
5.18 UNMET NEEDS
5.19 IMPACT OF 2025 US TARIFF ON BOTULINUM TOXINS MARKET
5.19.1 INTRODUCTION
5.19.2 KEY TARIFF RATES
5.19.3 PRICE IMPACT ANALYSIS
5.19.4 IMPACT ON COUNTRY/REGION
5.19.4.1 North America
5.19.4.1.1 US
5.19.4.2 Europe
5.19.4.3 Asia Pacific
5.19.5 IMPACT ON END-USE INDUSTRIES
5.20 IMPACT OF AI/GEN AI ON BOTULINUM TOXINS MARKET
5.20.1 MARKET POTENTIAL OF AI/GEN AI
5.20.2 AI USE CASES
5.20.3 KEY COMPANIES IMPLEMENTING AI/GEN AI
5.20.4 FUTURE OF AI/GEN AI

6 BOTULINUM TOXINS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 BOTOX
6.2.1 USE IN THERAPEUTIC AND COSMETIC PROCEDURES TO AUGMENT MARKET GROWTH
6.3 DYSPORT
6.3.1 FASTER ONSET DURATION AND LONG-LASTING EFFECT TO BOOST MARKET ADOPTION
6.4 JEUVEAU
6.4.1 INTRODUCTION OF TECH-ENABLED PLATFORMS FOR CONSUMER SUPPORT TO FUEL MARKET GROWTH
6.5 MYOBLOC
6.5.1 WIDE THERAPEUTIC PROFILE TO DRIVE MARKET
6.6 XEOMIN
6.6.1 STABLE THERAPEUTIC PERFORMANCE AND EFFECTIVE FORMULATION TO FAVOR MARKET GROWTH
6.7 OTHER PRODUCTS

7 BOTULINUM TOXINS MARKET, BY TYPE
7.1 INTRODUCTION
7.2 TYPE A BOTULINUM TOXINS
7.2.1 GLOBAL CLINICAL ACCEPTANCE AND PROVEN EFFICACY TO SUPPORT MARKET GROWTH
7.3 TYPE B BOTULINUM TOXINS
7.3.1 WIDE THERAPEUTIC UTILITY AND DISTINCT CLINICAL PROFILE TO PROPEL MARKET GROWTH

8 BOTULINUM TOXINS MARKET, BY AGE GROUP
8.1 INTRODUCTION
8.2 17 YEARS OR YOUNGER
8.2.1 INCREASING THERAPEUTIC USE OF BOTOX TO PROPEL MARKET GROWTH AMONG YOUNGER PEOPLE
8.3 18-34 YEARS
8.3.1 GOOD TOLERABILITY AND IMPROVED PATIENT-REPORTED OUTCOMES TO DRIVE ADOPTION OF BOTOX TREATMENT
8.4 35-50 YEARS
8.4.1 NEED FOR APPEARANCE MAINTENANCE AND BETTER SOCIAL ENGAGEMENT TO FUEL MARKET GROWTH
8.5 51-64 YEARS OLD
8.5.1 SUSTAINED DEMAND FOR COSMETIC AND THERAPEUTIC INDICATIONS TO AUGMENT MARKET GROWTH
8.6 65 YEARS OR OLDER
8.6.1 HIGH DEMAND FOR FUNCTIONAL IMPROVEMENTS AND CONSERVATIVE AESTHETIC ENHANCEMENTS TO DRIVE MARKET

9 BOTULINUM TOXINS MARKET, BY APPLICATION
9.1 INTRODUCTION
9.2 COSMETIC APPLICATIONS
9.2.1 WRINKLE REMOVAL
9.2.1.1 Surge in beauty clinics and medical spas to support segment growth
9.2.2 FACIAL CONTOURING
9.2.2.1 Rising desire for natural results and growing appeal of minimally invasive procedures to propel segment growth
9.2.3 SKIN REJUVENATION
9.2.3.1 Increased adoption of minimally invasive facial enhancement procedures to boost market growth
9.3 THERAPEUTIC APPLICATIONS
9.3.1 PAIN MANAGEMENT
9.3.1.1 Rising need for pain management techniques to drive segment
9.3.2 OVERACTIVE BLADDER
9.3.2.1 Localized mechanism, strong efficacy, and long-lasting relief to spur demand for botulinum toxins among neurogenic patients
9.4 OTHER APPLICATIONS

10 BOTULINUM TOXINS MARKET, BY END USER
10.1 INTRODUCTION
10.2 DERMATOLOGY CLINICS & HOSPITALS
10.2.1 RISING TREND OF MEDICAL TOURISM AND INCREASING POPULARITY OF PLASTIC SURGERY TO SUPPORT MARKET GROWTH
10.3 BEAUTY CENTERS
10.3.1 GROWING INCLINATION TOWARD CUSTOMIZED TREATMENTS TO BOOST MARKET GROWTH
10.4 MEDICAL SPAS
10.4.1 INCREASING FOCUS ON CONVENIENCE, TREATMENT FLEXIBILITY, AND COST EFFECTIVENESS TO SPUR MARKET GROWTH
10.5 OTHER END USERS

11 BOTULINUM TOXINS MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 US to dominate North American botulinum toxins market during study period
11.2.3 CANADA
11.2.3.1 Preference for minimally invasive cosmetic procedures among aging individuals to drive market growth
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 Selective reimbursement regimes and large number of cosmetic procedures to spur market demand
11.3.3 UK
11.3.3.1 Increased demand for Botox for cosmetic enhancements to propel market growth
11.3.4 FRANCE
11.3.4.1 Increased awareness and broader societal acceptance of cosmetic treatments to augment market growth
11.3.5 ITALY
11.3.5.1 Rising number of medical aesthetic procedures to aid market growth
11.3.6 SPAIN
11.3.6.1 Growing availability of safe and effective minimally invasive or non-invasive aesthetic treatments to aid market growth
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 JAPAN
11.4.2.1 Popularity of medical tourism to increase demand for cosmetic treatments
11.4.3 CHINA
11.4.3.1 Surging demand for non-surgical aesthetic procedures to support market growth
11.4.4 INDIA
11.4.4.1 Lack of reimbursements for aesthetic treatments alongside social and ethical concerns to limit market growth
11.4.5 AUSTRALIA
11.4.5.1 Increased number of aesthetic procedures to grow market for botulinum toxins
11.4.6 SOUTH KOREA
11.4.6.1 Rising availability of safe and effective minimally invasive and non-invasive aesthetic procedures and products to drive market
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Rapid growth in medical tourism and high disposable incomes to expedite market growth
11.5.3 MEXICO
11.5.3.1 Rising influx of medical tourists from US to drive adoption of cost-effective cosmetic procedures
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
11.6.2 GCC COUNTRIES
11.6.2.1 Favorable government policies to propel market growth
11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYERS' STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BOTULINUM TOXINS MARKET
12.3 REVENUE ANALYSIS, 2020-2024
12.4 MARKET SHARE ANALYSIS, 2024
12.4.1 MARKET RANKING OF KEY PLAYERS, 2024
12.5 COMPANY VALUATION & FINANCIAL METRICS
12.5.1 FINANCIAL METRICS
12.5.2 COMPANY VALUATION
12.6 BRAND/PRODUCT COMPARISON
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.7.1 STARS
12.7.2 PERVASIVE PLAYERS
12.7.3 EMERGING LEADERS
12.7.4 PARTICIPANTS
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.7.5.1 Company footprint
12.7.5.2 Region footprint
12.7.5.3 Type footprint
12.7.5.4 Application footprint
12.7.5.5 End-user footprint
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.8.1 PROGRESSIVE COMPANIES
12.8.2 RESPONSIVE COMPANIES
12.8.3 DYNAMIC COMPANIES
12.8.4 STARTING BLOCKS
12.8.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2024
12.8.5.1 Detailed list of key startups/SMEs
12.8.5.2 Competitive benchmarking of key startups/SMEs
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES & APPROVALS
12.9.2 DEALS
12.9.3 EXPANSIONS

13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 ABBVIE INC.
13.1.1.1 Business overview
13.1.1.2 Products offered
13.1.1.3 Recent developments
13.1.1.3.1 Deals
13.1.1.3.2 Expansions
13.1.1.3.3 Other developments
13.1.1.4 MnM view
13.1.1.4.1 Key strengths
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses & competitive threats
13.1.2 IPSEN BIOPHARMACEUTICALS, INC.
13.1.2.1 Business overview
13.1.2.2 Products offered
13.1.2.3 Recent developments
13.1.2.3.1 Product approvals
13.1.2.3.2 Expansions
13.1.2.3.3 Other developments
13.1.2.4 MnM view
13.1.2.4.1 Key strengths
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses & competitive threats
13.1.3 GALDERMA
13.1.3.1 Business overview
13.1.3.2 Products offered
13.1.3.3 Recent developments
13.1.3.3.1 Product launches
13.1.3.3.2 Deals
13.1.3.3.3 Expansions
13.1.3.4 MnM view
13.1.3.4.1 Key strengths
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses & competitive threats
13.1.4 HUGEL, INC.
13.1.4.1 Business overview
13.1.4.2 Products offered
13.1.4.3 Recent developments
13.1.4.3.1 Product approvals
13.1.4.3.2 Deals
13.1.4.3.3 Expansions
13.1.4.4 MnM view
13.1.4.4.1 Key strengths
13.1.4.4.2 Strategic choices
13.1.4.4.3 Weaknesses & competitive threats
13.1.5 REVANCE
13.1.5.1 Business overview
13.1.5.2 Products offered
13.1.5.3 Recent developments
13.1.5.3.1 Product launches & approvals
13.1.5.3.2 Deals
13.1.5.4 MnM view
13.1.5.4.1 Key strengths
13.1.5.4.2 Strategic choices
13.1.5.4.3 Weaknesses & competitive threats
13.1.6 EVOLUS, INC.
13.1.6.1 Business overview
13.1.6.2 Products offered
13.1.6.3 Recent developments
13.1.6.3.1 Product launches & approvals
13.1.6.3.2 Deals
13.1.7 MEDYTOX
13.1.7.1 Business overview
13.1.7.2 Products offered
13.1.7.3 Recent developments
13.1.7.3.1 Product approvals
13.1.7.3.2 Deals
13.1.8 MERZ PHARMA
13.1.8.1 Business overview
13.1.8.2 Products offered
13.1.8.3 Recent developments
13.1.8.3.1 Product approvals
13.1.9 SUPERNUS PHARMACEUTICALS, INC.
13.1.9.1 Business overview
13.1.9.2 Products offered
13.1.10 DAEWOONG PHARMACEUTICAL CO., LTD.
13.1.10.1 Business overview
13.1.10.2 Products offered
13.1.10.3 Recent developments
13.1.10.3.1 Product launches & approvals
13.1.11 HUONS
13.1.11.1 Business overview
13.1.11.2 Products offered
13.1.11.3 Recent developments
13.1.11.3.1 Product launches & approvals
13.1.12 EISAI CO., LTD.
13.1.12.1 Business overviewn
13.1.12.2 Products offered
13.1.13 HUGH SOURCE (INTERNATIONAL) LTD.
13.1.13.1 Business overview
13.1.13.2 Products offered
13.2 OTHER PLAYERS
13.2.1 DERMAX CO., LTD.
13.2.2 GUFIC BIOSCIENCES
13.2.3 OCEAN PHARMACEUTICAL
13.2.4 CROMA-PHARMA GMBH
13.2.5 MICROGEN
13.2.6 JDBIO CO., LTD.
13.2.7 CKD BIO
13.2.8 ATRAZIST ARAY CO.
13.2.9 GUANGZHOU AOMA BUSINESS CO., LTD.
13.2.10 JETEMA CO., LTD.
13.2.11 SINOPHARM GROUP CO., LTD.
13.2.12 QUFU HANTANG BIOTECHNOLOGY CO., LTD.

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS